Effectiveness of probiotics in combined therapy of atopic dermatitis

2017 ◽  
pp. 77-80
Author(s):  
S.M. Nedelska ◽  
◽  
O.D. Kuznietsova ◽  
O.O. Shevchenko ◽  
I.A. Kizilova ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Combined Therapy

scholarly journals Experience of combined topical therapy with methylprednisoloni aceponatis and «Bepanten Plus»® in treatment of adult patients with moderate and severe atopic dermatitis

2015 ◽  
Vol 12 (6) ◽  
pp. 80-83
Author(s):  
O K Shtyrbul ◽  
O A Erina ◽  
E S Fedenko
Keyword(s):  
Staphylococcus Aureus ◽  
Atopic Dermatitis ◽  
Combined Therapy ◽  
Topical Therapy ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Bacterial Isolation ◽  
Treatment Results ◽  
Lesional Skin ◽  
Days Of Therapy

Background. To estimate efficiency of combined therapy with methylprednisolone aceponatis and «Bepanten Plus»® in adult patients with moderate and severe atopic dermatitis. Methods. We examined 32 adult patients, who were treated with TGCS methylprednisolone aceponatis and «Bepanten Plus»®. The efficiency of therapy was estimated with index SCORAD, IGA and subjective patients assessment. For 15 of 32 patients swabs for bacterial isolation to estimate Staphylococcus aureus growth were taken from lesional skin before therapy and on the 14 th or 20 th days of treatment. Results. The аverage value of index SCORAD decreased after 15 days of therapy, Me 41,7 to Me 23,3 a point (p

scholarly journals EMOLLIENT MILK XEMOSE IN THERAPY OF ATOPIC DERMATITIS IN CHILDREN

2014 ◽  
Vol 11 (4) ◽  
pp. 59-63
Author(s):  
E T KINDEEVA ◽  
N G KOROTKII ◽  
A N PAMPURA
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Efficacy ◽  
Combined Therapy ◽  
Allergic Inflammation ◽  
Skin Barrier ◽  
Skin Surface ◽  
Skin Lesions ◽  
Transepidermal Water Loss ◽  
Skin Barrier Function ◽  
Epidermal Barrier

Background. Structural and functional damages of the epidermal barrier in patients with atopic dermatitis promote the entry of allergens and development of Th2-type allergic inflammation. Moisturizers containing lipids increase the physiological antiinflammatory effects of topical corticosteroids (TGKS), improve the epidermal barrier and reduce the duration of TGKS using preventing further infringement barrier. To evaluate the clinical efficacy of emollient milk Xemose in children with atopic dermatitis. Materials and methods. We examined 27 children with atopic dermatitis. Children were divided into 2 groups: patients in group 1 (n=14) used emollient milk Xemose twice a day on the skin lesions and limbs in the complex therapy, patients in the 2nd group (n=13) received combined therapy incorporating traditional dampening agents on the basis of lanolin (Unna cream) 3 times daily. All patients underwent measurement of transepidermal water loss (TEWl) (Tewameter TM 300, Multi Probe Adapter MPA 5/9, Courage + Khazaka) and the pH of the skin (Skin-pH-Meter, Multi Probe Adapter MPA 5/9, Courage + Khazaka) before and after 2 weeks of therapy. Results. Patients in groupthat used Xemose milk and children in group with Unna cream after 2 weeks showed a statistically significant decrease of TEWl (p=0,041 and p=0,04, respectively). TEWl was significantly lower in children treated for 2 weeks with milk Xemose (p=0,027) than in children treated with Unna cream. in both groups pH skin surface have not changed (р=0,22 and р=0,22 respectively). Conclusion. Clinical efficacy of milk Xemose as compound improving skin barrier function in children with atopic dermatitis was shown.

scholarly journals Modern emollients impact on the damaged skin barrier at children with atopic dermatitis

2013 ◽  
Vol 10 (4) ◽  
pp. 65-68
Author(s):  
E T Kindeeva ◽  
A N Pampura
Keyword(s):  
Atopic Dermatitis ◽  
Combined Therapy ◽  
Skin Barrier ◽  
Skin Surface ◽  
Skin Lesions ◽  
Transepidermal Water Loss ◽  
Surface Ph ◽  
Before And After ◽  
Skin Surface Ph ◽  
Group 1

Introduction. Damaged skin barrier has significant role in the pathogenesis of atopic dermatitis (AD). Use of emollients is reasonable for skin care of AD patients. Background. To compare the clinical efficacy of Kserodian plus with traditional moisturizer (cream Unna) at children with atopic dermatitis. Materials and methods. The study included 31 children with AD. Children were divided into 2 groups: patients in group 1 (n=8) used Kserodian plus 2 times daily for skin lesions and limbs in the complex therapy, patients in the 2nd group (n=13) received combined therapy incorporating traditional dampening agent on the basis of lanolin (cream Unna) 3 times daily. All patients underwent measurement of transepidermal water loss (TEWL) (Tewameter TM 300, Multi Probe Adapter MPA 5/9, Courage + Khazaka) and the pH of the skin (SkinpHMeter, Multi Probe Adapter MPA 5/9, Courage + Khazaka) before and after 2 weeks of therapy. Results. Kserodian plus decreased erythema, dryness of the skin, itching, square of leasons in all the patients. Statistically significant decrease in the values of TEWL and skin surface pH (p

scholarly journals Bacterially Delivered miRNA-Mediated Toll-like Receptor 8 Gene Silencing for Combined Therapy in a Murine Model of Atopic Dermatitis: Therapeutic Effect of miRTLR8 in AD

2021 ◽  
Vol 9 (8) ◽  
pp. 1715
Author(s):  
Wonsuck Yoon ◽  
Eun-Jae Kim ◽  
Yongsung Park ◽  
Seunghyun Kim ◽  
Yong-Keun Park ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Oral Administration ◽  
Gene Silencing ◽  
Combined Therapy ◽  
Adaptive Immune Response ◽  
Skin Inflammation ◽  
Interleukin 4 ◽  
Therapeutic Effects ◽  
Skin Reactions ◽  
Adaptive Immune

In atopic dermatitis (AD), skin inflammation is caused by complex interactions between genetic disposition and aberrant innate/adaptive immune responses. Toll-like receptors (TLRs) are key molecules in the innate/adaptive immune response as they recognize various molecular motifs associated with pathogens. Among them, TLR8 is implicated in eczematous skin reactions. We investigated the combined therapeutic effects of TLR8 gene silencing by the bacterial delivery of miRNA. We used Salmonella as a vector to deliver TLR8 miRNA. The recombinant strain of Salmonella enterica subsp. enterica serovar Typhimurium (ST) expressing TLR8 miRNA (ST-miRTLR8) was prepared for knockdown of TLR8. After oral administration of ST-miRTLR8 into mice, we observed the cytokine levels, skin pathology and scratching behaviors in an AD-like mouse model. TLR8 down-regulation decreased macrophage-derived chemokine concentrations in activated human mast cells. Serum IgE and interleukin-4 production were suppressed whereas IFN-γ was induced after oral administration of ST-miRTLR8. Scratching behaviors and skin inflammation were also improved. In addition, attenuated S. typhimurium safely accumulated in mouse macrophages and showed adjuvant effects. This study shows that the recombinant miRNA that expresses the TLR8 miRNA has therapeutic effects by suppressing Th2 inflammation. TLR gene modulation using miRNA via Salmonella vectors will thus have a double-protective effect in the treatment of AD.

scholarly journals SKIN-CAP IN THE TREATMENT OF CHRONIC DERMATOSES.Medica l Techno logy

2010 ◽  
Vol 7 (1) ◽  
pp. 66-70
Author(s):  
L F Znamenskaya ◽  
T A Goryacheva ◽  
S V Yakovleva ◽  
N V Kungurov ◽  
M M Kokhan ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Events ◽  
Medical Technology ◽  
Clinical Presentation ◽  
Combined Therapy ◽  
Therapeutic Action ◽  
Fungal Contamination ◽  
Treatment Algorithms

This Medical Technology summarizes therapeutic action and treatment algorithms of Skin-Cap in atopic dermatitis management depending on clinical presentation, stage and adverse events. Skin-cap as a part of the combined therapy decreases microbial and fungal contamination of the skin and minimizes other very active agents usage. The licence for it's administration is available at www.roszdravnadzor.ru

Sign in / Sign up

Export Citation Format

Share Document